Eiger Biopharmaceuticals Inc
Business Description
Eiger Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company located in Palo Alto, California. It was founded in 2008 with the aim of developing and commercializing innovative therapies for rare and ultra-rare diseases. The company*s primary focus is on the development of novel small-molecule drugs that target specific diseases with unmet medical needs.
Eiger Biopharmaceuticals is committed to addressing diseases that affect a small patient population and lack effective treatment options. The company employs a rigorous and comprehensive approach to drug development, utilizing scientific expertise, strategic partnerships, and a deep understanding of the underlying biology of diseases.
One of the key therapeutic areas of Eiger Biopharmaceuticals is in the field of Hepatitis Delta Virus (HDV) infection. HDV is considered the most severe form of viral hepatitis and affects approximately 15-20 million people worldwide. Eiger Biopharmaceuticals is dedicated to developing a potential first-in-class drug candidate, lonafarnib, for the treatment of HDV.
In addition to HDV, Eiger Biopharmaceuticals is actively researching and developing therapies for other rare diseases, including autoimmune diseases and metabolic disorders. The company has a pipeline of drug candidates in various stages of development, with promising results from preclinical and early-stage clinical studies.
Eiger Biopharmaceuticals has established strategic partnerships and collaborations with leading academic institutions, government agencies, and pharmaceutical companies to accelerate the development and commercialization of its therapies. They work closely with regulatory agencies to ensure compliance with strict safety and efficacy standards.
The company places great emphasis on patient-centeredness and prioritizes the needs of patients in its drug development efforts. Eiger Biopharmaceuticals actively engages with patient advocacy groups and aims to provide innovative and effective treatment options that can improve the lives of patients.
Overall, Eiger Biopharmaceuticals is a dedicated and innovative biopharmaceutical company that is driven by the mission to develop life-changing therapies for patients with rare and ultra-rare diseases. Through its rigorous research and development programs, strategic partnerships, and patient-centric approach, the company is committed to making a lasting impact on the field of biopharmaceuticals.
|